KR860004060A - 티에닐 축합 피라졸 유도체의 제조방법 - Google Patents

티에닐 축합 피라졸 유도체의 제조방법 Download PDF

Info

Publication number
KR860004060A
KR860004060A KR1019850008256A KR850008256A KR860004060A KR 860004060 A KR860004060 A KR 860004060A KR 1019850008256 A KR1019850008256 A KR 1019850008256A KR 850008256 A KR850008256 A KR 850008256A KR 860004060 A KR860004060 A KR 860004060A
Authority
KR
South Korea
Prior art keywords
pyrazole derivatives
compound
condensed pyrazole
preparing
alkyl
Prior art date
Application number
KR1019850008256A
Other languages
English (en)
Other versions
KR900003496B1 (ko
Inventor
스스무 다까다 (외 4)
Original Assignee
요시또시 가즈오
시오노기 세이야꾸 가부시끼가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 요시또시 가즈오, 시오노기 세이야꾸 가부시끼가이샤 filed Critical 요시또시 가즈오
Publication of KR860004060A publication Critical patent/KR860004060A/ko
Application granted granted Critical
Publication of KR900003496B1 publication Critical patent/KR900003496B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/30—Hetero atoms other than halogen
    • C07D333/36—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

내용 없음

Description

티에닐 축합 피라졸 유도체의 제조방법
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (1)

  1. 하기 일반식(II)의 화합물을 염기 또는 산으로 고리화하여 하기 일반식(Ia)의 화합물을 수득하고, 화합물(Ia)를 탈에스테르화 한후, 탈카르복실화 함을 특징으로 하는 하기 일반식(Ic)의 화합물의 제조방법.
    (상기 식중 R1및 R2는 각각 수소, 알킬, 알콕시카르보닐, 카르복시, 할로겐, 니트로 또는 트리플루오로메틸이거나, R1및 R2는 함께 알킬렌을 형성할 수 있으며, X는 수소, 알킬, 알콕시, 할로겐 또는 히드록시이고, Y는 메틴 또는 질소이며, A는 이탈기이고, R은 알킬이다)
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019850008256A 1984-11-05 1985-11-05 티에닐 축합 피라졸 유도체의 제조방법 KR900003496B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP233511 1984-11-05
JP233511/1984 1984-11-05
JP59233511A JPS61112075A (ja) 1984-11-05 1984-11-05 チエニルピラゾロキノリン誘導体

Publications (2)

Publication Number Publication Date
KR860004060A true KR860004060A (ko) 1986-06-16
KR900003496B1 KR900003496B1 (ko) 1990-05-21

Family

ID=16956169

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019850008256A KR900003496B1 (ko) 1984-11-05 1985-11-05 티에닐 축합 피라졸 유도체의 제조방법

Country Status (8)

Country Link
US (1) US4690930A (ko)
EP (1) EP0182165B1 (ko)
JP (1) JPS61112075A (ko)
KR (1) KR900003496B1 (ko)
CA (1) CA1269983A (ko)
DE (1) DE3572358D1 (ko)
ES (1) ES8701173A1 (ko)
GB (1) GB2166439B (ko)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4814450A (en) * 1984-07-09 1989-03-21 Ciba-Geigy Corporation Certain ring-fused pyrazolo[3,4-d]-pyridin-3-one derivatives
US4826854A (en) * 1986-11-25 1989-05-02 Ciba-Geigy Corporation Certain cycloalka-(b)-pyrazolo(3,4-d)-pyridin-3-one derivatives
EP0478964A1 (en) * 1990-09-06 1992-04-08 Shionogi Seiyaku Kabushiki Kaisha Pyrazoloquinoline derivatives
US5442062A (en) * 1991-10-24 1995-08-15 The Upjohn Company Imidazole derivatives and pharmaceutical compositions containing the same
AR006520A1 (es) * 1996-03-20 1999-09-08 Astra Pharma Prod Derivados de 2-arilpirazolisoquinolina y cinolinona y procedimiento para su preparacion.
GB9713707D0 (en) 1997-06-27 1997-09-03 Merck Sharp & Dohme Therapeutic agents
WO1999064425A1 (en) * 1998-06-09 1999-12-16 Neurogen Corporation Substituted thienocycloalkylpyrazoles: dopamine receptor subtype specific ligands
US6756382B2 (en) 1999-06-10 2004-06-29 3M Innovative Properties Company Amide substituted imidazoquinolines
DE60234057D1 (de) 2001-07-25 2009-11-26 Raptor Pharmaceutical Inc Zusammensetzungen und verfahren zur modulation des transports durch die blut-hirn-schranke
SE0202461D0 (sv) * 2002-08-14 2002-08-14 Astrazeneca Ab Novel compounds
BRPI0412902A (pt) 2003-08-12 2006-09-26 3M Innovative Properties Co compostos contendo imidazo substituìdo por oxima
WO2005020999A1 (en) 2003-08-27 2005-03-10 3M Innovative Properties Company Aryloxy and arylalkyleneoxy substituted imidazoquinolines
US20050054665A1 (en) 2003-09-05 2005-03-10 3M Innovative Properties Company Treatment for CD5+ B cell lymphoma
US7544697B2 (en) * 2003-10-03 2009-06-09 Coley Pharmaceutical Group, Inc. Pyrazolopyridines and analogs thereof
ES2544477T3 (es) 2003-10-03 2015-08-31 3M Innovative Properties Company Imidazoquinolinas sustituidas con alcoxi
CA2545825A1 (en) 2003-11-14 2005-06-02 3M Innovative Properties Company Hydroxylamine substituted imidazo ring compounds
CN1906193A (zh) 2003-11-14 2007-01-31 3M创新有限公司 肟取代的咪唑环化合物
NZ547467A (en) 2003-11-25 2010-06-25 3M Innovative Properties Co Substituted imidazo ring system and methods
WO2005066170A1 (en) 2003-12-29 2005-07-21 3M Innovative Properties Company Arylalkenyl and arylalkynyl substituted imidazoquinolines
JP2007517044A (ja) 2003-12-30 2007-06-28 スリーエム イノベイティブ プロパティズ カンパニー イミダゾキノリニル、イミダゾピリジニル、およびイミダゾナフチリジニルスルホンアミド
AU2005228150A1 (en) 2004-03-24 2005-10-13 3M Innovative Properties Company Amide substituted imidazopyridines, imidazoquinolines, and imidazonaphthyridines
WO2005123080A2 (en) 2004-06-15 2005-12-29 3M Innovative Properties Company Nitrogen-containing heterocyclyl substituted imidazoquinolines and imidazonaphthyridines
WO2006065280A2 (en) 2004-06-18 2006-06-22 3M Innovative Properties Company Isoxazole, dihydroisoxazole, and oxadiazole substituted imidazo ring compounds and methods
WO2006009826A1 (en) 2004-06-18 2006-01-26 3M Innovative Properties Company Aryloxy and arylalkyleneoxy substituted thiazoloquinolines and thiazolonaphthyridines
US7897609B2 (en) 2004-06-18 2011-03-01 3M Innovative Properties Company Aryl substituted imidazonaphthyridines
WO2006083440A2 (en) 2004-12-30 2006-08-10 3M Innovative Properties Company Substituted chiral fused [1,2]imidazo[4,5-c] ring compounds
US7943609B2 (en) 2004-12-30 2011-05-17 3M Innovative Proprerties Company Chiral fused [1,2]imidazo[4,5-C] ring compounds
JP2008530022A (ja) 2005-02-04 2008-08-07 コーリー ファーマシューティカル グループ，インコーポレイテッド 免疫反応調節物質を含む水性ゲル処方物
AU2006213746A1 (en) 2005-02-11 2006-08-17 Coley Pharmaceutical Group, Inc. Oxime and hydroxylamine substituted imidazo(4,5-c) ring compounds and methods
US7943610B2 (en) 2005-04-01 2011-05-17 3M Innovative Properties Company Pyrazolopyridine-1,4-diamines and analogs thereof
CA2602590A1 (en) 2005-04-01 2006-10-12 Coley Pharmaceutical Group, Inc. 1-substituted pyrazolo (3,4-c) ring compounds as modulators of cytokine biosynthesis for the treatment of viral infections and neoplastic diseases
DK1889198T3 (da) 2005-04-28 2015-02-09 Proteus Digital Health Inc Farma-informatiksystem
WO2008008432A2 (en) 2006-07-12 2008-01-17 Coley Pharmaceutical Group, Inc. Substituted chiral fused( 1,2) imidazo (4,5-c) ring compounds and methods
US8795627B2 (en) 2007-03-21 2014-08-05 Raptor Pharmaceuticals Inc. Treatment of liver disorders by administration of RAP conjugates
EP2166852B1 (en) * 2007-06-08 2012-02-08 Helicon Therapeutics, Inc. Therapeutic pyrazoloquinoline derivatives
ES2483728T3 (es) * 2007-06-08 2014-08-07 Dart Neuroscience (Cayman) Ltd Derivados terapéuticos de pirazolonafatiridina
US7863266B2 (en) * 2007-06-08 2011-01-04 Helicon Therapeutics, Inc. Therapeutic pyrazoloquinoline urea derivatives
ES2728225T3 (es) 2009-02-20 2019-10-23 2 Bbb Medicines B V Sistema de administración de fármacos a base de glutatión
US8486946B2 (en) 2009-02-23 2013-07-16 Merck Sharp & Dohme Corp. Pyrazolo [4,3-c] cinnolin-3-one M1 receptor positive allosteric modulators
EP2427178B1 (en) 2009-05-06 2023-01-04 Laboratory Skin Care, Inc. Dermal delivery compositions comprising active agent-calcium phosphate particle complexes and methods of using the same
EP2490692B1 (en) * 2009-10-21 2016-11-16 Merck Sharp & Dohme Corp. Quinolinone-pyrazolone m1 receptor positive allosteric modulators
US20120077778A1 (en) 2010-09-29 2012-03-29 Andrea Bourdelais Ladder-Frame Polyether Conjugates
US8653079B2 (en) 2011-08-15 2014-02-18 Merck Sharp & Dohme Corp. Pyrazolo [4,3-C] cinnolin-3-one M1 receptor positive allosteric modulators

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4312870A (en) * 1979-06-21 1982-01-26 Ciba-Geigy Corporation Pyrazoloquinolines
ATE8629T1 (de) * 1979-06-21 1984-08-15 Ciba-Geigy Ag Pyrazolochinoline, verfahren zu ihrer herstellung, und pharmazeutische praeparate enthaltend diese verbindungen.
US4524146A (en) * 1982-12-08 1985-06-18 Ciba-Geigy Corporation Certain -2-heterocycle substituted pyrazoloquinolines
US4479955A (en) * 1983-01-10 1984-10-30 Ciba-Geigy Corporation Heterocycle-fused pyrazolo[3,4-d]pyridin-3-ones as benzodiazepine receptor modulators
FR2549833B1 (fr) * 1983-07-26 1985-11-08 Roussel Uclaf Derives de la pyrazolo /4,3-c/ cinnolin-3-one, leurs sels, procede de preparation, application a titre de medicaments, compositions les renfermant et produits intermediaires

Also Published As

Publication number Publication date
CA1269983A (en) 1990-06-05
US4690930A (en) 1987-09-01
JPH0370706B2 (ko) 1991-11-08
EP0182165B1 (en) 1989-08-16
EP0182165A1 (en) 1986-05-28
ES548534A0 (es) 1986-12-01
ES8701173A1 (es) 1986-12-01
DE3572358D1 (de) 1989-09-21
KR900003496B1 (ko) 1990-05-21
GB8527227D0 (en) 1985-12-11
GB2166439A (en) 1986-05-08
JPS61112075A (ja) 1986-05-30
GB2166439B (en) 1988-08-03

Similar Documents

Publication Publication Date Title
KR860004060A (ko) 티에닐 축합 피라졸 유도체의 제조방법
KR850003890A (ko) 1H-이미다조[4,5c]-퀴놀린-4-아민의 제조방법
KR850003402A (ko) 2-아미노-5-하이드록시-4-메틸 피리미딘 유도체의 제조방법
KR860003210A (ko) 알킬설폰 아미도 페닐알킬 아민의 제조 방법
SE8004194L (sv) 1-bensylimidazolderivat
SE8703169L (sv) 1-(4-aminofenyl)-4-metyl-7,8-metylendioxi-3,4-dihydro-5h-2,3-bensodiazepin, syraadditionssalter derav samt forfarande for framstellning av densamma
KR840005101A (ko) 2-퀴놀린유도체의 제조방법
KR850006187A (ko) 신규 히달토인(Hydantoin) 유도체의 제조방법
PT81545B (pt) Processo para a preparacao de compostos 5-aloquil-1-fenil-2-piperazino-alquil-pirazolin-3-ona
KR920701120A (ko) 치환된 비시클로헵탄디온 유도체
KR830004320A (ko) 퀴나졸린 유도체의 제조방법
KR830004210A (ko) 2-아미노-3-벤조일-페닐아세트아미드 및 환상 동족체
AU575972B2 (en) 3- aminocarbonylmethoxy - 5 - phenylpyrazole derivatives
KR900700103A (ko) 항-알레르기성 점안제
ATE48993T1 (de) Aetheroxidderivate von zyklopropylphenolen.
ATE83481T1 (de) Fuenfgliedrige heterocyclische derivate von n'substituiertenn,n'-diacylhydrazinen.
KR860008983A (ko) 4- 벤조일-1- 알킬(알켄일) 피라졸의 제조방법
KR840006238A (ko) 신규 α-아릴-α-피리딜알카노인산 유도체의 제조방법
KR850000415A (ko) 퀴나졸리논 유도체의 제조방법
KR870004038A (ko) 제초제 화합물의 제조방법
ES500810A0 (es) Procedimiento de preparacion de aminoalcoxipirazoles
KR840001160A (ko) 벤조디옥산-이미다졸린 유도체의 제조방법
KR830010090A (ko) 아닐린 유도체의 제조방법
KR830006176A (ko) 치환된 펜옥시-아미노프로판올 유도체의 제조방법
KR840009102A (ko) 치환된 이소퀴놀린 유도체의 제조방법

Legal Events

Date Code Title Description
A201 Request for examination
G160 Decision to publish patent application
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 19951227

Year of fee payment: 7

LAPS Lapse due to unpaid annual fee